The global AntP1 antibody market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of autoimmune diseases and rising demand for immunoassays in research and diagnostics.
Monoclonal antibodies are expected to dominate the global AntP1 antibody market during the forecast period, owing to their high specificity and sensitivity. Polyclonal antibodies are also expected to witness significant growth due to their lower cost as compared with monoclonal antibodies.
-The global Anti-PD-1 Antibody market is expected to grow at a CAGR of around 16.5% during the forecast period, owing to the increasing incidence of cancer and rising awareness about cancer prevention. -Increasing prevalence rates for cancers such as lung, breast, prostate, colon and pancreatic are driving demand for anti PD 1 antibodies in these regions.
Increasing prevalence rates for cancers such as lung, breast, prostate, colon and pancreatic are driving demand for anti PD 1 antibodies in these regions. -The high cost associated with treatment is also driving growth in this market segment due to increased affordability with newer drugs coming into the market that offer better efficacy than older drugs without compromising on safety or tolerability profiles.
Industry Growth Insights published a new data on “Anti-PD-1 Antibody Market”. The research report is titled “Anti-PD-1 Antibody Market research by Types (Monoclonal, Polyclonal), By Applications (IHC-P, ICC/IF, WB, Flow Cytometry, ELISA), By Players/Companies Bio X Cell, Thermo Fisher, InvivoGen, BioVision Inc, Abcam, Bristol-Myers Squibb (BMS), Merck, Ono Pharmaceutical Co., Ltd, Lilly, Chugai Pharmaceutical Co., Ltd, BeiGene, Abbvie, TG Therapeutics, Inc, Novartis, Arcus Biosciences, Sino Biological Inc, 3SBio Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-PD-1 Antibody Market Research Report
By Type
Monoclonal, Polyclonal
By Application
IHC-P, ICC/IF, WB, Flow Cytometry, ELISA
By Companies
Bio X Cell, Thermo Fisher, InvivoGen, BioVision Inc, Abcam, Bristol-Myers Squibb (BMS), Merck, Ono Pharmaceutical Co., Ltd, Lilly, Chugai Pharmaceutical Co., Ltd, BeiGene, Abbvie, TG Therapeutics, Inc, Novartis, Arcus Biosciences, Sino Biological Inc, 3SBio Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Anti-PD-1 Antibody Market Report Segments:
The global Anti-PD-1 Antibody market is segmented on the basis of:
Types
Monoclonal, Polyclonal
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
IHC-P, ICC/IF, WB, Flow Cytometry, ELISA
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bio X Cell
- Thermo Fisher
- InvivoGen
- BioVision Inc
- Abcam
- Bristol-Myers Squibb (BMS)
- Merck
- Ono Pharmaceutical Co., Ltd
- Lilly
- Chugai Pharmaceutical Co., Ltd
- BeiGene
- Abbvie
- TG Therapeutics, Inc
- Novartis
- Arcus Biosciences
- Sino Biological Inc
- 3SBio Inc
Highlights of The Anti-PD-1 Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal
- Polyclonal
- By Application:
- IHC-P
- ICC/IF
- WB
- Flow Cytometry
- ELISA
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-PD-1 Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-PD-1 antibody is a type of antibody that fights cancer.
Some of the key players operating in the anti-pd-1 antibody market are Bio X Cell, Thermo Fisher, InvivoGen, BioVision Inc, Abcam, Bristol-Myers Squibb (BMS), Merck, Ono Pharmaceutical Co., Ltd, Lilly, Chugai Pharmaceutical Co., Ltd, BeiGene, Abbvie, TG Therapeutics, Inc, Novartis, Arcus Biosciences, Sino Biological Inc, 3SBio Inc.
The anti-pd-1 antibody market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-PD-1 Antibody Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-PD-1 Antibody Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-PD-1 Antibody Market - Supply Chain
4.5. Global Anti-PD-1 Antibody Market Forecast
4.5.1. Anti-PD-1 Antibody Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-PD-1 Antibody Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anti-PD-1 Antibody Market Absolute $ Opportunity
5. Global Anti-PD-1 Antibody Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anti-PD-1 Antibody Market Size and Volume Forecast by Type
5.3.1. Monoclonal
5.3.2. Polyclonal
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anti-PD-1 Antibody Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anti-PD-1 Antibody Market Size and Volume Forecast by Application
6.3.1. IHC-P
6.3.2. ICC/IF
6.3.3. WB
6.3.4. Flow Cytometry
6.3.5. ELISA
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anti-PD-1 Antibody Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anti-PD-1 Antibody Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anti-PD-1 Antibody Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anti-PD-1 Antibody Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anti-PD-1 Antibody Demand Share Forecast, 2019-2026
9. North America Anti-PD-1 Antibody Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anti-PD-1 Antibody Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anti-PD-1 Antibody Market Size and Volume Forecast by Application
9.4.1. IHC-P
9.4.2. ICC/IF
9.4.3. WB
9.4.4. Flow Cytometry
9.4.5. ELISA
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anti-PD-1 Antibody Market Size and Volume Forecast by Type
9.7.1. Monoclonal
9.7.2. Polyclonal
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anti-PD-1 Antibody Demand Share Forecast, 2019-2026
10. Latin America Anti-PD-1 Antibody Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anti-PD-1 Antibody Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anti-PD-1 Antibody Market Size and Volume Forecast by Application
10.4.1. IHC-P
10.4.2. ICC/IF
10.4.3. WB
10.4.4. Flow Cytometry
10.4.5. ELISA
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anti-PD-1 Antibody Market Size and Volume Forecast by Type
10.7.1. Monoclonal
10.7.2. Polyclonal
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anti-PD-1 Antibody Demand Share Forecast, 2019-2026
11. Europe Anti-PD-1 Antibody Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anti-PD-1 Antibody Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anti-PD-1 Antibody Market Size and Volume Forecast by Application
11.4.1. IHC-P
11.4.2. ICC/IF
11.4.3. WB
11.4.4. Flow Cytometry
11.4.5. ELISA
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anti-PD-1 Antibody Market Size and Volume Forecast by Type
11.7.1. Monoclonal
11.7.2. Polyclonal
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractivenes/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anti-PD-1 Antibody Demand Share, 2019-2026
12. Asia Pacific Anti-PD-1 Antibody Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anti-PD-1 Antibody Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anti-PD-1 Antibody Market Size and Volume Forecast by Application
12.4.1. IHC-P
12.4.2. ICC/IF
12.4.3. WB
12.4.4. Flow Cytometry
12.4.5. ELISA
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anti-PD-1 Antibody Market Size and Volume Forecast by Type
12.7.1. Monoclonal
12.7.2. Polyclonal
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anti-PD-1 Antibody Demand Share, 2019-2026
13. Middle East & Africa Anti-PD-1 Antibody Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anti-PD-1 Antibody Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anti-PD-1 Antibody Market Size and Volume Forecast by Application
13.4.1. IHC-P
13.4.2. ICC/IF
13.4.3. WB
13.4.4. Flow Cytometry
13.4.5. ELISA
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anti-PD-1 Antibody Market Size and Volume Forecast by Type
13.7.1. Monoclonal
13.7.2. Polyclonal
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anti-PD-1 Antibody Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anti-PD-1 Antibody Market: Market Share Analysis
14.2. Anti-PD-1 Antibody Distributors and Customers
14.3. Anti-PD-1 Antibody Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bio X Cell
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Thermo Fisher
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. InvivoGen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BioVision Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abcam
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb (BMS)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ono Pharmaceutical Co., Ltd
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Lilly
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Chugai Pharmaceutical Co., Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. BeiGene
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Abbvie
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. TG Therapeutics, Inc
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Novartis
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Arcus Biosciences
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Sino Biological Inc
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. 3SBio Inc
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
